ArticleSensors (Basel, Switzerland)2018
A Novel Microfluidic Point-of-Care Biosensor System on Printed Circuit Board for Cytokine Detection.
Article in Sensors (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 56 citations in OpenAlex.
- A mechanically robust wearable sweat analysis platform with plug-and-play interconnects for continuous biomarker profiling.Microsystems & nanoengineering · 2026Article
- Nano-Enabled Microfluidic Platforms for Functional Immunomonitoring in Pediatric Sepsis.International journal of nanomedicine · 2026Review
- An Organ-on-a-Chip Modular Platform with Integrated Immunobiosensors for Monitoring the Extracellular Environment.Micromachines · 2025Article
- Development of a direct PMMA-PCB bonding method for low cost and rapid prototyping of microfluidic-based gas analysers.RSC advances · 2024Article
- Cloth-based microfluidic devices integrated onto the patch as wearable colorimetric sensors for simultaneous sweat analysis.BioImpacts : BI · 2023Article
- Review
- Microfluidics as a Novel Technique for Tuberculosis: From Diagnostics to Drug Discovery.Microorganisms · 2021Review
- Point-of-care detection of cytokines in cytokine storm management and beyond: Significance and challenges.View (Beijing, China) · 2021Review
- Cytokines: From Clinical Significance to Quantification.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Review
- Affinity biosensors developed with quantum dots in microfluidic systems.Emergent materials · 2021Review
- Printed Circuit Board (PCB) Technology for Electrochemical Sensors and Sensing Platforms.Biosensors · 2020Review
- Microfluidic Point-of-Care Devices: New Trends and Future Prospects for eHealth Diagnostics.Sensors (Basel, Switzerland) · 2020Article
- Performance Evaluation of Miniature Integrated Electrochemical Cells Fabricated Using LTCC Technology.Sensors (Basel, Switzerland) · 2019Article
- Modular Pressure and Flow Rate-Balanced Microfluidic Serial Dilution Networks for Miniaturised Point-of-Care Diagnostic Platforms.Sensors (Basel, Switzerland) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Point of Care (PoC) diagnostics have been the subject of considerable research over the last few decades driven by the pressure to detect diseases quickly and effectively and reduce healthcare costs. Herein, we demonstrate a novel, fully integrated, microfluidic amperometric enzyme-linked immunosorbent assay (ELISA) prototype using a commercial interferon gamma release assay (IGRA) as a model antibody binding system. Microfluidic assay chemistry was engineered to take place on Au-plated electrodes within an assay cell on a printed circuit board (PCB)-based biosensor system. The assay cell is linked to an electrochemical reporter cell comprising microfluidic architecture, Au working and counter electrodes and a Ag/AgCl reference electrode, all manufactured exclusively via standard commercial PCB fabrication processes. Assay chemistry has been optimised for microfluidic diffusion kinetics to function under continual flow. We characterised the electrode integrity of the developed platforms with reference to biological sampling and buffer composition and subsequently we demonstrated concentration-dependent measurements of H₂O₂ depletion as resolved by existing FDA-validated ELISA kits. Finally, we validated the assay technology in both buffer and serum and demonstrate limits of detection comparable to high-end commercial systems with the addition of full microfluidic assay architecture capable of returning diagnostic analyses in approximately eight minutes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.